• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 21, 2019 at 10:02: AM
via Emricasan, a caspase inhibitor, is being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis (NASH). Conatus acquired the worldwide rights to emricasan from Pfizer PFE in July 2010.

article source
 




Top Bottom
Back
Quote